<DOC>
	<DOC>NCT02739295</DOC>
	<brief_summary>NeupoNET aims to evaluate interest of G-CSF in the treatment of Toxic Epidermal necrolysis. This is a prospective randomized controlled trial. Patients will be allocated in a treatment group (receiving an injection of 5 microg/kg/d of G-CSF during 5 consecutive days) or in a placebo group. Patients will be randomized at admission and will be followed until 3 months after discharge.</brief_summary>
	<brief_title>G-CSF in the Treatment of Toxic Epidermal Necrolysis</brief_title>
	<detailed_description />
	<mesh_term>Stevens-Johnson Syndrome</mesh_term>
	<criteria>Toxic epidermal necrolysis with SCORTEN 1 to 5 at admission Toxic epidermal necrolysis with SCORTEN 6 or 7 at admission Hypercoagulable state Cardiac or peripheral arterial disease Active malignancy Myelodysplastic syndrome or hematological malignancy Fructose intolerance Pregnancy Patient refusal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>